Daily feed · SEC Form 4 filings
Insider buying in low-priced stocks — Sep 26, 2017
Open-market purchases where the filing’s own weighted average price is under $5. Price comes from the Form 4 itself, not a market quote.
| Trade | Reported (ET) | Company | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 21, 2017 PForm 4 → | Sep 25, 5:00 pm EDT | Xenon Pharmaceuticals Inc.XENE | Mohammad AzabDirector | 10,000 | $2.95 | $29,500 | 29,210 | +52.1% | plan? |
| Sep 22, 2017 PForm 4 → | Sep 25, 4:34 pm EDT | SCYNEXIS INCSCYX | Marco TagliettiChief Executive Officer, Director | 10,000 | $2.23 | $22,300 | 303,000 | +3.41% | plan? |
| Sep 25, 2017 PForm 4 → | Sep 25, 6:14 pm EDT | General Finance CORPGFN | Ronald ValentaChief Executive Officer, Director, 10% Owner | 2,900 | $4.98 | $14,446 | 4,585,976 | +0.06% | plan? |
| Sep 21, 2017 PForm 4 → | Sep 25, 5:27 pm EDT | Cerecor Inc.CERC | ARMISTICE CAPITAL, LLC +2Director, 10% Owner | 14,660 | $0.784 | $11,494 | 15,979,165 | +0.09% | plan? |
| Sep 25, 2017 PForm 4 → | Sep 25, 7:41 pm EDT | General Finance CORPGFN | Larry D TashjianDirector | 300 | $4.95 | $1,485 | 220,456 | +0.14% | plan? |
| Sep 26, 2017 PForm 4 → | Sep 26, 3:07 pm EDT | ANAVEX LIFE SCIENCES CORP.AVXL | Christopher U MisslingPresident and CEO, Director | 375 | $3.88 | $1,455 | 1,008,875 | +0.04% | plan? |
| Sep 25, 2017 PForm 4 → | Sep 25, 4:33 pm EDT | KEMPHARM, INCKMPH | R. LaDuane CliftonCFO, Secretary & Treasurer | 300 | $3.78 | $1,133 | 1,575 | +23.5% | plan? |
| Sep 22, 2017 PForm 4 → | Sep 26, 12:33 pm EDT | ENDONOVO THERAPEUTICS, INC.ENDV | Michael Scott MannPresident, 10% Owner | 20,000 | $0.0383 | $765 | 23,546,189 | +0.09% | plan? |
A trading day runs to 4:00 pm ET; filings accepted later appear on the next trading day. Rows aggregate a filing’s matching transaction lines — see the methodology for the exact roll-up rules.